Merker, Matthias
Kohl, Thomas A.
Barilar, Ivan
Andres, Sönke
Fowler, Philip W.
Chryssanthou, Erja
Ängeby, Kristian
Jureen, Pontus
Moradigaravand, Danesh
Parkhill, Julian
Peacock, Sharon J.
Schön, Thomas
Maurer, Florian P.
Walker, Timothy
Köser, Claudio
Niemann, Stefan
Funding for this research was provided by:
Wellcome Trust (214560/Z/18/Z)
Oscar II Jubilee Foundation (NA)
Health Innovation Challenge Fund (WT098600, HICF-T5-342)
German Center for Infection Research (NA)
Leibniz Science Campus “Evolutionary Medicine of the Lung” (NA)
Joachim Herz Stiftung
Article History
Received: 16 October 2019
Accepted: 25 February 2020
First Online: 6 March 2020
Ethics approval and consent to participate
: Not applicable
: Not applicable
: CUK is a consultant for the WHO Regional Office for Europe, Becton Dickinson, and QuantuMDx Group Ltd. CUK is an unpaid advisor to GenoScreen and consulted for the Foundation for Innovative New Diagnostics, which involved work for Cepheid Inc., Hain Lifescience, and WHO. The Bill & Melinda Gates Foundation and Hain Lifescience covered CUK’s travel and accommodation to present at meetings. The Global Alliance for TB Drug Development Inc. and Otsuka Novel Products GmbH have supplied CUK with antibiotics for in vitro research. YD Diagnostics has provided CUK with assays for an evaluation. JP is a paid consultant to Next Gen Diagnostics. All remaining authors declare that they have no competing interests.